Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
- Revenue in USD (TTM)172.63k
- Net income in USD-27.25m
- Incorporated1987
- Employees--
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY NSW 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tectonic Therapeutic Inc | 0.00 | 30.31m | 255.35m | 13.00 | 2.09 | 0.7296 | 8.35 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| AVITA Medical Inc | 50.70m | -44.82m | 264.19m | 207.00 | -- | 8.11 | -- | 5.21 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 264.30m | 123.00 | -- | 9.44 | -- | 6.90 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 266.26m | 137.00 | -- | 2.10 | -- | 2.95 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -25.20 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.58m | 285.80m | 140.00 | -- | 1.81 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 287.35m | 122.00 | -- | 2.74 | -- | 400.73 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 288.38m | 133.00 | -- | 1.56 | -- | 271.03 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Immutep Ltd - ADR | 172.63k | -27.25m | 288.52m | -- | -- | 3.08 | -- | 1,671.36 | -0.2625 | -0.2625 | 0.0016 | 0.6489 | 0.0025 | -- | 2.48 | -- | -38.61 | -- | -41.57 | -- | -- | -- | -15,782.59 | -- | -- | -- | 0.0138 | -- | -24.64 | -- | -23.86 | -- | -- | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 295.53m | 167.00 | -- | -- | -- | 1.58 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Omeros Corp | 0.00 | -179.09m | 301.31m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 304.65m | 168.00 | -- | 0.664 | -- | 7.51 | -3.36 | -3.36 | 0.5934 | 6.46 | 0.0775 | -- | 7.09 | 241,428.60 | -39.22 | -47.40 | -43.89 | -54.18 | -- | -- | -506.16 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| MacroGenics Inc | 43.36m | -23.24m | 320.06m | 339.00 | -- | 3.01 | -- | 7.38 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 320.48m | 275.00 | -- | 0.5868 | -- | 1.16 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 320.89m | 402.00 | -- | 2.64 | -- | 28.20 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Data as of Jul 22 2024. Currency figures normalised to Immutep Ltd's reporting currency: US Dollar USD
2.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Pengana Capital Ltd.as of 29 Feb 2024 | 980.61k | 0.78% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 749.46k | 0.59% |
| Oracle Investment Management, Inc.as of 31 Mar 2024 | 564.88k | 0.45% |
| Millennium Management LLCas of 31 Mar 2024 | 349.46k | 0.28% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 172.80k | 0.14% |
| Caption Management LLCas of 31 Mar 2024 | 73.29k | 0.06% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 66.44k | 0.05% |
| PFG Investments LLCas of 31 Mar 2024 | 51.00k | 0.04% |
| Virtu Americas LLCas of 31 Mar 2024 | 45.06k | 0.04% |
| BNP Paribas Financial Marketsas of 31 Mar 2024 | 35.30k | 0.03% |
More ▼
Data from 29 Feb 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
